Ascelia Pharma AB received a Complete Response Letter from the FDA regarding its NDA on July 3, 2026.
2 reports, 1 independent
Updated Sun 00:00
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ascelia Pharma AB received a Complete Response Letter from the FDA regarding its NDA on July 3, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Ascelia used the SPARKLE dataset following the FDA's Complete Response Letter.1 source
The FDA returned a Complete Response Letter on the NDA filed by Ascelia Pharma AB.1 source
Keep exploring
The entities involved
Related events
- Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
- The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.